Business
AbbVie Acquires Apogee Therapeutics
AbbVie is acquiring Apogee Therapeutics for nearly $11 billion, continuing a trend of pharmaceutical mergers. The deal includes the developer of an experimental atopic dermatitis drug.
Coverage timeline — 1 article
STAT News
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
2026-06-22 11:45 UTC